Advertisement
Organisation › Details
Gemoab GmbH
GEMoaB is a privately owned, clinical-stage biopharmaceutical company. GEMoaB is developing switchable universal CAR-T platforms (UniCAR and RevCAR) to improve the therapeutic window and increase efficacy and safety of CAR-T cell therapies in challenging cancers, including acute leukemias and solid tumors. Conventional CAR-T cells depend on the presence and direct binding of cancer antigens for activation and proliferation. An inherent key feature of the GEMoaB platforms is a switchable on/off mechanism enabled by pharmacokinetic half-life and internalization of soluble adaptors termed targeting modules (TMs). These TMs provide the antigen-specificity to activate UniCAR or RevCAR gene-modified T-cells (UniCAR-T or RevCAR-T) and consist of a highly flexible antigen-binding moiety, linked to a motif recognized by UniCAR-T or RevCAR-T respectively. GEMoaB has a broad pipeline of product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors. Its clinical stage assets GEM333, a T-cell engaging bispecific antibody (TCE) with binding specificity to CD33 in relapsed/refractory AML, and GEM3PSCA, a TCE with binding specificity to PSCA for the treatment of castrate-resistant metastatic prostate cancer and other PSCA expressing late-stage solid tumors, are currently investigated in Phase I studies and globally partnered with Bristol-Myers Squibb. Phase I studies of the lead UniCAR assets UniCAR-T-CD123 in hematological malignancies and UniCAR-T-PSMA in solid tumors are currently recruiting patients. Clinical proof-of-concept data were recently published in Blood and at key scientific meetings including the 3rd EHA-EBMT European CAR T-Cell Meeting and the 2021 AACR Annual Meeting. *
Start | 2020-10-19 renamed | |
Group | Cellex (Group) | |
Predecessor | Gemoab Monoclonals GmbH | |
Industry | CAR T-cell therapy product | |
Industry 2 | cancer immunotherapy (immuno-oncology, I-O) | |
Person | Pehl, Michael (Adcendo 202107– CEO before Gemoab + Immunomedics + Celgene + Amgen) | |
Person 2 | Ehninger, Gerhard (Cellex 202106 Managing Director + Founder of Cellex + Gemoab) | |
Region | Dresden | |
Country | Germany | |
Street | 47 Tatzberg | |
City | 01307 Dresden | |
Tel | +49-531-4466-4500 | |
Address record changed: 2021-10-17 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Blackstone. (6/22/21). "Press Release: Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company". Cambridge, MA. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Cellex (Group)
- [1] Adcendo ApS. (7/6/21). "Press Release: Adcendo Appoints Michael Pehl as Chief Executive Officer"....
- [2] Gemoab GmbH. (7/20/20). "Press Release: Gemoab and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy". Dresden....
- [3] Gemoab GmbH. (7/16/19). "Press Release: Gemoab Announces the Appointment of Oncology Expert Michael Pehl as Chief Executive Officer". Dresden....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top